AbbVie (ABBV) Other Operating Expenses (2012 - 2026)

AbbVie has disclosed Other Operating Expenses across 15 years of filings, most recently posting $5.0 billion for Q1 2026.

• In Q1 2026, Other Operating Expenses rose 16.75% year-over-year to $5.0 billion; the TTM figure through Mar 2026 stood at $5.2 billion (up 22.22% YoY), while the FY2025 annual figure was $241.0 million, up 3342.86% from the prior year.
• Other Operating Expenses improved to $5.0 billion in Q1 2026, from $217.0 million in the prior quarter.
• Over the last five years, Other Operating Expenses for ABBV reached as high as $5.0 billion in Q1 2026 and fell as low as -$229.0 million in Q3 2022.
• The 5-year median for Other Operating Expenses is $96.5 million (2023), against an average of $958.3 million.
• Annual changes were most pronounced in 2022 — Other Operating Expenses sank 145.8% — and 2025, when it jumped 3000.0%.
• A 5-year view of Other Operating Expenses shows it stood at $1.0 million in 2022, then jumped by 16800.0% to $169.0 million in 2023, then plunged by 95.86% to $7.0 million in 2024, then jumped by 3000.0% to $217.0 million in 2025, then surged by 2186.64% to $5.0 billion in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $5.0 billion, $217.0 million, and $24.0 million for Q1 2026, Q4 2025, and Q2 2025 respectively.